The Decrease in Cytokine Concentration During Albumin Dialysis Correlates With the Prognosis of Patients With Acute on Chronic Liver Failure

• Published in: Transplantation proceedings Vol. 37; no. 6; pp. 2551 - 2553
• Main Authors: Di Campli, C., Zocco, M.A., Gaspari, R., Novi, M., Candelli, M., Santoliquido, A., Flore, R., Tondi, P., Proietti, R., Gasbarrini, G., Pola, P., Gasbarrini, A.
• Format: Journal Article Conference Proceeding
• Language: English
• Published: New York, NY Elsevier Inc 01.07.2005; Elsevier Science
• Subjects: Adult; Ammonia - blood; Bilirubin - blood; Biological and medical sciences; Child, Preschool; Chronic Disease; Cytokines - blood; Female; Fundamental and applied biological sciences. Psychology; Fundamental immunology; Gastroenterology. Liver. Pancreas. Abdomen; Humans; Interleukins - blood; Liver Failure - therapy; Liver Failure, Acute - therapy; Liver. Biliary tract. Portal circulation. Exocrine pancreas; Male; Medical sciences; Middle Aged; Other diseases. Semiology; Renal Dialysis - methods; Sorption Detoxification - methods; Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases; Tissue, organ and graft immunology; Tumor Necrosis Factor-alpha - analysis; Human; Prognosis; Acute; Cytokine; Albumin; Hepatic disease; Patient; Transplantation; Concentration; Medicine; Chronic; Liver failure; Treatment; Decrease; Surgery; Digestive diseases; Graft; Dialysis
• ISSN: 0041-1345; 1873-2623
• DOI: 10.1016/j.transproceed.2005.06.040

The clearance of plasma cytokines by means of albumin dialysis (MARS) has been demonstrated in various studies involving patients affected by either acute liver failure (ALF) or acute on chronic liver failure. The aim of the study was to measure the plasma levels of TNF-α, IL-6, and IL-1β in patients with ALF after each MARS treatment to evaluate the relationship between variations in cytokines levels and patient prognosis. Ten patients with ALF undergoing several MARS treatments were enrolled (group 1). Blood samples were collected before and after each MARS treatment to measure TNF-α, IL-6, and IL-1β, and other hematochemical parameters. We also enrolled 10 patients with ALF who underwent standard therapy (group 2) as well as a control group of 10 healthy subjects matched for sex and age (group 3). MARS reduced total bilirubin levels, biliary acids, BUN, ammonia, TNF-α, IL-6, and IL-1β ( P < .05). Moreover, the reduction in inflammatory cytokines levels and improved prognosis were related. We confirmed the therapeutic efficacy of MARS treatment for ALF, which appeared to be related to removal of toxins and inflammatory cytokines determine that which patients prognosis.